Researchers at Penn Dental Medicine and collaborators have used a clinical-grade antiviral chewing gum to substantially reduce viral loads of two herpes simplex viruses and two influenza A strains in experimental models.
a chewing gum made from lablab beans, Lablab purpureus—that naturally contain an antiviral trap protein (FRIL)—to neutralize two herpes simplex viruses (HSV-1 and HSV-2) and two influenza A strains (H1N1 and H3N2). The chewing gum formulation allowed for effective and consistent release of FRIL at sites of viral infection.
They demonstrated that 40 milligrams of a two-gram bean gum tablet was adequate to reduce viral loads by more than 95%, a reduction similar to what they saw in their SARS-CoV-2 study.